Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.
Soligenix, Inc. reports developments as a late-stage biopharmaceutical company focused on rare diseases and public health medical countermeasures. Company news centers on HyBryte (synthetic hypericin), a visible-light activated therapy program for cutaneous T-cell lymphoma, and SGX945 (dusquetide) for Behçet's Disease, including clinical data, published study results and regulatory designations.
Updates also cover the Public Health Solutions segment, including RiVax ricin toxin vaccine candidate, filovirus vaccine programs, CiVax for COVID-19 and the ThermoVax heat-stabilization platform. Recurring announcements include operating and financial results, government-supported development activities, material agreements, shareholder voting matters and governance updates.
Soligenix, Inc. (Nasdaq: SNGX) announced its participation in upcoming conferences like the Aegis Virtual Conference, BioNJ's 14th Annual BioPartnering Conference, and A.G.P./Alliance Global Partners Healthcare Company Showcase. These events provide opportunities for presentations, networking, and one-on-one meetings with key members of Soligenix management. The Company aims to deliver a corporate presentation to investors, institutional funds, and money managers, showcasing its late-stage biopharmaceutical products for rare diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.